Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Science Board's Report: Legislative Negotiating Tactic, Or Just Whining For Money?

Executive Summary

21st Century Cures criticized by FDA advisors for unfunded mandates, but legislation also represents best near-term prospect for reforms of the kind the report envisions.


Related Content

US FDA Progress Report Highlights Biomarkers, Continuous Manufacturing, Antibiotic Testing
FDA Relocates To Lake Wobegon? Most Applications Deemed Above Average, Researchers Find
Science Evolution At FDA ‘Transformative,’ Advisors Say
Califf’s Trial Design Prescription: Less Randomization, More Transparency
Show Me The Money: FDA Recruitment Efforts Challenged By Government Salaries
FDA Should Look Through IIRIS To Improve Science, Panel Says; Funding Is Worry


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts